AXIM Initiates New Studies & Pulls Ahead of the Competition — – SYS

REDONDO BEACH, CA — (Marketwired) — 11/07/16 —, a leading financial news and information portal offering free real time public company filing alerts, announces an article taking a closer look at AXIM Biotechnologies’ (OTCQB: AXIM) cannabinoid-based clinical trials program.

AXIM is advancing their patented controlled-release cannabinoid gum in studies covering a number of indications. The company’s flagship CanChew Plus® contains 10mg

... read more at: